Efficacy of Turmeric-Boswellia Formulation for Acute Low Back Pain: A Double-blind, Randomized, Placebo-controlled Trial

ABSTRACT

Objectives: To evaluate the efficiency of the turmeric-Boswellia formulation (TBF, Rhuleave-K) in reducing acute low back pain (LBP) among healthy subjects. Materials and Methods: This research aimed to assess the effectiveness of TBF compared to a placebo through a single dose of 1,000 mg, administered in a randomized, double-blinded, placebo-controlled trial with 76 participants experiencing acute low back pain. Efficacy was evaluated using objective outcome measures, namely the numerical rating scale (NRS), categorical pain relief scale (PRS), the onset of analgesia, and the short-form McGill questionnaire. NRS and PRS measurements were taken 30 minutes post-dose at rest, during movement, and under pressure application at the afflicted area. The onset of analgesia was assessed 6 hours post-dose. Quantitative analysis of the Sum of Pain intensity Difference (SPID) and Total Pain Relief (TOTPAR) values was conducted based on the NRS and PRS scores, respectively. Results: Pain relief began quickly and all participants in the TBF group reported a significantly noticeable reduction in pain at about 76.4 minutes, compared to the 190 minutes in the placebo group. Similarly, 92.7% of participants in the TBF group experienced mean meaningful pain relief (MPR) as early as 224.1 minutes, compared to the zero MPR responders in the placebo group. There was a statistically significant difference in the time to pain relief between the TBF and placebo groups, with significant improvement in the TBF group (log-rank hazard ratio, p < 0.001). None of the individuals in the placebo group demonstrated a minimum of 50% maximum TOTPAR in rest, movement, and pressure. Whereas, 75.71% of the TBF group experienced at least 50% maximum TOTPAR in rest, 88.09% in movement, and 90.48% in pressure. The effectiveness of the treatment, as measured by the number needed to treat (NNT) for achieving at least 50% of MPR in the TBF group, was 1.2 at rest and 1.1 during both movement and pressure. Conclusion: Oral administration of TBF (Rhuleave-K) to individuals with acute low back pain significantly reduces pain, providing meaningful relief within 4 hours of administration. This highlights the substantial analgesic effectiveness of TBF in the context of acute LBP.

KEYWORDS

• Low back pain
• pain intensity
• turmeric
• Boswellia
• Rhuleave-K
• pain relief

Showing references and in-text citations exactly as published.

• DOI10.1177/09731296241281438Copy

RELATED ARTICLES

Matched on section and article type within this issue of Pharmacogn. Mag..

• Article · VOLUME 21, ISSUE 2Pinobanksin Attenuates Cerebral Ischemia– Reperfusion Injury in Rats through Mitigating the Inflammatory ResponsesTianmin Bie, Feng Jia, Yongmei Wang, Zhuoyan Pan · pp. 413–422Original Research ArticleSame type: Article
• Article · VOLUME 21, ISSUE 2Extraction and in vitro and in vivo Antioxidant Activity Evaluation of Polyphenols from Lychee PericarpYing Wang, Hong Deng, Chuqin Yu, Junfeng Ban, Shu Zhang · pp. 423–432Original Research ArticleSame type: Article
• Article · VOLUME 21, ISSUE 2Discussion about the Role of Ghrelin in Myocardial Ischemia/Reperfusion and its Possible MechanismGang Huang, Nan Zheng, Yinqing Huang · pp. 433–442Original Research ArticleSame type: Article
• Article · VOLUME 21, ISSUE 2Sanggenol L Reduces LPS-induced Myocardial Injury and Inflammation by Activating PI3K/ AKT/mTOR and Inhibiting NF-κB in RatsHaojun Wang, Tao Jin, Yuehan Mao, Yi Wei · pp. 443–453Original Research ArticleSame type: Article